[go: up one dir, main page]

MX2019004942A - Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma. - Google Patents

Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.

Info

Publication number
MX2019004942A
MX2019004942A MX2019004942A MX2019004942A MX2019004942A MX 2019004942 A MX2019004942 A MX 2019004942A MX 2019004942 A MX2019004942 A MX 2019004942A MX 2019004942 A MX2019004942 A MX 2019004942A MX 2019004942 A MX2019004942 A MX 2019004942A
Authority
MX
Mexico
Prior art keywords
bcl
antibody
inhibitor
combination
hodgkin
Prior art date
Application number
MX2019004942A
Other languages
English (en)
Inventor
Boxhammer Rainer
Endell Jan
Petropoulos Konstantin
Kelemen Peter
Rückert Markus
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2019004942A publication Critical patent/MX2019004942A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente divulgación describe una combinación farmacéutica de un anticuerpo anti-CD19 y un inhibidor de BCL-2 para el tratamiento de linfoma no Hodgkin, leucemia linfocítica crónica y/o leucemia linfoblástica aguda.
MX2019004942A 2016-10-28 2017-10-27 Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma. MX2019004942A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16196184 2016-10-28
PCT/EP2017/077654 WO2018078123A1 (en) 2016-10-28 2017-10-27 Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
MX2019004942A true MX2019004942A (es) 2019-08-12

Family

ID=57218739

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019004942A MX2019004942A (es) 2016-10-28 2017-10-27 Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.
MX2022016270A MX2022016270A (es) 2016-10-28 2019-04-26 Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022016270A MX2022016270A (es) 2016-10-28 2019-04-26 Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.

Country Status (26)

Country Link
US (1) US12358983B2 (es)
EP (2) EP3903821A1 (es)
JP (3) JP7094950B2 (es)
KR (2) KR20230028571A (es)
CN (2) CN118045175A (es)
AU (2) AU2017348624B2 (es)
BR (1) BR112019008244A2 (es)
CA (1) CA3037246A1 (es)
CY (1) CY1124648T1 (es)
DK (1) DK3532098T3 (es)
ES (1) ES2871574T3 (es)
HR (1) HRP20210838T1 (es)
HU (1) HUE054496T2 (es)
IL (3) IL320372A (es)
LT (1) LT3532098T (es)
MX (2) MX2019004942A (es)
NZ (1) NZ751414A (es)
PL (1) PL3532098T3 (es)
PT (1) PT3532098T (es)
RS (1) RS62036B1 (es)
RU (1) RU2756405C2 (es)
SG (1) SG10202104036QA (es)
SI (1) SI3532098T1 (es)
SM (1) SMT202100347T1 (es)
WO (1) WO2018078123A1 (es)
ZA (1) ZA201903302B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3954388A1 (en) 2015-08-21 2022-02-16 MorphoSys AG Combinations and uses thereof
PT3532098T (pt) 2016-10-28 2021-06-17 Morphosys Ag Combinação de anticorpo anti cd19 com um inibidor bcl-2 e suas utilizações
FI3630177T3 (fi) 2017-05-31 2023-10-18 Morphosys Ag Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CA3107085A1 (en) * 2018-08-31 2020-03-05 Adc Therapeutics Sa Combination of anti-cd19 antibody-pyrroloenzodiazepine conjugate and ve netoclax
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
CN114786723A (zh) * 2019-10-31 2022-07-22 莫佛塞斯公司 序贯抗cd19疗法
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
CA2422076A1 (en) 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
EP1461423B1 (en) 2001-12-03 2008-05-14 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
EP1899379B1 (en) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19 antibodies and their uses
DK2270050T3 (da) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
AU2007285976B2 (en) 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
BRPI0716661B1 (pt) 2006-08-15 2019-05-21 Hydralift Amclyde, Inc. Aparelho e método para prover compensação de levantamento para uma carga suspensa de uma extremidade de um cabo em um ambiente marinho, com a outra extremidade do cabo.
CA2662340C (en) 2006-09-08 2016-08-02 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
ES2599172T3 (es) 2007-10-19 2017-01-31 Seattle Genetics, Inc. Agentes de unión a CD19 y usos de éstos
US20100128586A1 (en) 2008-11-25 2010-05-27 Mediatek Inc. Method and apparatus for accessing data from disc with linking area
BRPI1005984A2 (pt) 2009-02-23 2016-10-04 Glenmark Pharmaceuticals Sa anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US20120128586A1 (en) 2009-06-24 2012-05-24 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
US20120087915A1 (en) 2010-06-03 2012-04-12 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
US8549399B2 (en) 2011-01-18 2013-10-01 Apple Inc. Identifying a selection of content in a structured document
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
LT2744515T (lt) * 2011-08-16 2022-04-25 Morphosys Ag Kombinuota terapija su anti-cd19 antikūnu ir azoto garstyčiomis
CN103703027B (zh) * 2011-08-16 2018-01-12 莫佛塞斯公司 使用抗cd‑19抗体和嘌呤类似物的联合治疗
KR101813830B1 (ko) * 2013-12-05 2017-12-29 에프. 호프만-라 로슈 아게 친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물
ES2818110T3 (es) 2014-02-28 2021-04-09 Merck Sharp & Dohme Tratamiento del cáncer con una combinación que comprende dinaciclib
SG11201606909RA (en) * 2014-04-07 2016-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
CN106794231A (zh) 2014-06-16 2017-05-31 赞科股份有限公司 用于慢性淋巴细胞性白血病（cll）的治疗
JP7057669B2 (ja) 2014-10-20 2022-04-20 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法において投薬するための方法および組成物
SG11201705476WA (en) * 2015-02-12 2017-09-28 Seattle Genetics Inc Combination therapy using a cd19-adc and vincristine
BR112017023517A2 (pt) 2015-05-26 2018-07-24 F. Hoffmann-La Roche Ag anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
EP3302550B1 (en) 2015-05-26 2019-08-28 MorphoSys AG Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
BR112017028530A2 (pt) 2015-07-02 2018-08-28 Celgene Corp terapia combinada para tratamento de cânceres hematológicos e tumores sólidos
EP3954388A1 (en) 2015-08-21 2022-02-16 MorphoSys AG Combinations and uses thereof
MD3465214T2 (ro) 2016-05-30 2021-09-30 Morphosys Ag Metode de predicție a beneficiului terapeutic al terapiei anti-CD19 la pacienți
ES2874640T3 (es) 2016-06-27 2021-11-05 Morphosys Ag Formulaciones de anticuerpos anti-CD19
PT3532098T (pt) 2016-10-28 2021-06-17 Morphosys Ag Combinação de anticorpo anti cd19 com um inibidor bcl-2 e suas utilizações
FI3630177T3 (fi) 2017-05-31 2023-10-18 Morphosys Ag Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
KR20220007087A (ko) 2019-05-03 2022-01-18 모르포시스 아게 제한된 수의 nk 세포를 갖는 환자에서의 항-cd19 치료제
IL292181A (en) 2019-10-31 2022-06-01 Morphosys Ag Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
DK4051710T3 (da) 2019-10-31 2025-12-15 Incyte Corp Antitumor-kombinationsterapi bestående af anti-cd19-antistof og gamma-delta-t-celler
CN114786723A (zh) 2019-10-31 2022-07-22 莫佛塞斯公司 序贯抗cd19疗法
TW202216193A (zh) 2020-06-22 2022-05-01 德商莫菲西斯公司 包含抗CD19抗體及阻斷SIRPα-CD47先天免疫檢查點之多肽之抗腫瘤組合療法
IL303384A (en) 2020-12-04 2023-08-01 Morphosys Ag Anti-CD19 combination therapy
MX2024007649A (es) 2021-12-22 2024-08-26 Incyte Corp Paradigma de tratamiento para una terapia con anticuerpos anti cumulo de diferenciacion (anti-cd19).

Also Published As

Publication number Publication date
CN109890418A (zh) 2019-06-14
RU2019113370A3 (es) 2021-03-01
CA3037246A1 (en) 2018-05-03
IL266216B1 (en) 2023-05-01
MX2022016270A (es) 2023-02-15
ES2871574T3 (es) 2021-10-29
IL320372A (en) 2025-06-01
CY1124648T1 (el) 2022-07-22
AU2024287178A1 (en) 2025-01-23
IL266216B2 (en) 2023-09-01
AU2017348624B2 (en) 2024-09-26
ZA201903302B (en) 2021-04-28
EP3903821A1 (en) 2021-11-03
CN118045175A (zh) 2024-05-17
AU2017348624A1 (en) 2019-03-28
RS62036B1 (sr) 2021-07-30
SG10202104036QA (en) 2021-05-28
US12358983B2 (en) 2025-07-15
WO2018078123A1 (en) 2018-05-03
LT3532098T (lt) 2021-06-25
CN109890418B (zh) 2024-03-08
KR20230028571A (ko) 2023-02-28
RU2756405C2 (ru) 2021-09-30
PT3532098T (pt) 2021-06-17
JP2024167208A (ja) 2024-12-03
IL301786B1 (en) 2025-05-01
IL301786B2 (en) 2025-09-01
BR112019008244A2 (pt) 2019-07-16
NZ751414A (en) 2025-10-31
JP2022137089A (ja) 2022-09-21
HRP20210838T1 (hr) 2021-08-06
IL266216A (en) 2019-06-30
HUE054496T2 (hu) 2021-09-28
JP2019533682A (ja) 2019-11-21
KR20190075942A (ko) 2019-07-01
SI3532098T1 (sl) 2021-12-31
EP3532098A1 (en) 2019-09-04
US20190241656A1 (en) 2019-08-08
EP3532098B1 (en) 2021-04-07
JP7094950B2 (ja) 2022-07-04
SMT202100347T1 (it) 2021-07-12
PL3532098T3 (pl) 2022-01-31
IL301786A (en) 2023-05-01
DK3532098T3 (da) 2021-05-25
KR102500868B1 (ko) 2023-02-16
RU2019113370A (ru) 2020-11-30

Similar Documents

Publication Publication Date Title
MX2019004942A (es) Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.
MX392561B (es) Combinación sinérgica de un anticuerpo anti-cd19 y un inhibidor de fosfoinositida 3-quinasa para usarse en el tratamiento de linfoma no hodgkin, leucemia linfocítica crónica y/o leucemia linfoblástica aguda.
CY1122298T1 (el) Συνδυασμος αντισωματος anτι-cd19 και αναστολεα τυροσινης κινασης toy bruton και χρησεις του
IL271266A (en) Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia
WO2016062722A8 (en) Combination
MX2021002888A (es) Combinaciones farmacéuticas para el tratamiento de tumores que comprenden un anticuerpo anti cúmulo de diferenciación 19 (cd19) y una célula asesina natural.
DOP2017000150A (es) Anticuerpos anti-cd 38 para el tratamiento de leucemia mieloides aguda
MX394170B (es) Anticuerpos anti-transtiretina
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
CR20180141A (es) Anticuerpos anti-cd 19 humano humanizados y métodos de utilización
CY1125122T1 (el) Θεραπεια συνδυασμου me anti-cd19 αντισωμα και μουσταρδα αζωτου
MX385019B (es) Dispositivo de manejo de película inflable.
MX2020002613A (es) Accionador lineal de alta reduccion impulsado por correas.
CO2017008469A2 (es) Anticuerpos anti-transtiretina
WO2018007922A3 (en) Anti-transthyretin antibodies
JP1644696S (ja) 自動車
MX353589B (es) Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina.
BR112015019924A2 (pt) métodos e composições para tratar leucemia
JP1644697S (ja) 自動車
MX2017005601A (es) Dispositivo, en particular para cerrar una region superior de un recipiente de productos alimenticios hecho de un laminado que tiene una region de borde que es desbastada y parcialmente plegada sobre si misma.
EP3770192A4 (en) DENIC RUBBER LATEX, ITS MANUFACTURING PROCESS, AND GRAFT COPOLYMER WITH CORE-ENVELOPE STRUCTURE CONTAINING IT
JP1644691S (ja) 自動車
MX2016011753A (es) Casete de tratamiento de la sangre con la valvula de pelicula y el espaciador elastico, asi como aparato de tratamiento de la sangre.
EP3674076A4 (en) STRETCH SHEET FOR ABSORBENT AND USER ABSORBENT ITEM
AR115621A1 (es) Laminados estirables polidimensionales